Navigation Links
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Date:6/30/2009

on in patients undergoing infertility management, it is believed that it will have a major implication on the decision-making process when choosing the appropriate gonadotropin for ovarian stimulation.[1]

"I think the cost-effectiveness of treatments is a real issue for couples considering infertility treatment such as IVF today", says Clare Lewis-Jones from Infertility Network UK. "Despite the economic downturn, we see that couples will somehow find the money for treatment, although many have to make sacrifices in order to do this - it's a question of priorities and the opportunity of having a family is an extremely high priority for infertile couples."

MENOPUR

MENOPUR belongs to a class of drugs known as gonadotropins and contains both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). HP-hMG is used to stimulate the development of multiple follicles in women participating in an ART programme. HP-hMG is also used to treat infertility in women caused by anovulation (low-level production of eggs). MENOPUR is used by over 75,000 patients each year and is currently licensed in over 50 countries across the world

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring's fertility portfolio of treatments gives infertile couples the chance to have babies and includes its flagship brand MENOPUR (HP-hMG), a recognised high quality treatment for infertility. Ferring has operating subsidiaries in over 45 countries. To learn more about Ferring or our products please visit http://www.ferring.com.

References:

1. Wex
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and t:flex™ ... public offering of 5,250,000 shares of its common stock ... share.  The net proceeds to Tandem from this offering ... discounts and commissions and other estimated offering expenses payable ...
(Date:2/26/2015)... SOUTH BEND, Ind. , Feb. 26, 2015 /PRNewswire/ ... to announce an agreement with Bank of America (NYSE: ... for consumers nationwide to receive financing of the revolutionary ... accessible vehicle, designed from the ground up to provide ... users. Approved applicants can use their loan to purchase ...
(Date:2/26/2015)... DALLAS , February 26, 2015 ... EU Outlook 2015: First -In- Class Innovations and ... Business for Large Cap Pharmaceutical Companies research report ... According to this Global Pharma US ... divested as productivity measurements, divestment of non-core assets ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4
(Date:2/27/2015)... 2015 Cocaine is an extreme stimulant, ... depression and hostility. In a joint effort between Australian ... of cocaine, may soon rejoice in what has been ... addictive biological response of cocaine, according to 7 ... researchers discovered that the brain is continually communicating with ...
(Date:2/27/2015)... 27, 2015 With support from Google, the ... at MoMath, a new collaboration offering Title I schools in ... museum in North America on ten days over the next ... 6-8 from seven schools in the Bronx and Queens will ... , MoMath strives to fulfill the incredible demand for hands-on ...
(Date:2/27/2015)... February 27, 2015 Burien Nursing ... American Health Care, Inc. with the Facility of ... in four key areas: Outstanding quality of care / ... Administrator Lynda Baldwin was invited to attend the awards ... 2015. “I am delighted to receive this award on ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... applications for its next class of Fellows — one ... of radiology business management. , Since 2009, the ... contributions made by RBMA members to the Association and ... prestigious recognition because each Fellow candidate must meet a ...
(Date:2/27/2015)... 27, 2015 The report “Polycystic ... comprehensive information on the therapeutic development for polycystic ... in which a woman's hormones are out of ... among teenage girls and young women. The cause ... strengthens R&D pipelines by identifying new targets and ...
Breaking Medicine News(10 mins):Health News:A New Study May Have an Answer to Treating Cocaine Addiction 2Health News:A New Study May Have an Answer to Treating Cocaine Addiction 3Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 3Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:RBMA Issues Call for Fellowship Applicants 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4
... Sydney Brenner, H. Robert Howvitz and John. E. Sulston ... or medicine. The prize has been awarded by the ... discoveries concerning genetic regulation// of organ development and programmed ... 1960’s, that fundamental questions regarding cell differentiation and organ ...
... that cloned animals tend to harbor genetic defects that ... the rational that reproductive cloning of humans should be ... be used safely for therapeutic cloning techniques, such as ... Parkinson's to diabetes. Cloned animals have major ...
... was observed that giving most heart attack patients an ... hospital could dramatically improve their chances of survival. The ... attacks with the extra fuel reduced the risk of ... only for patients whose hearts had not suffered substantial ...
... to a new study, stuttering could be caused by ... brain that triggers nerve disconnection in the regions controlling ... report chronic stuttering seems to be the result of ... hemisphere, the area responsible for speech. To demonstrate this, ...
... new study justifies that children with sleep-disordered breathing ... the study shows a tremendous improvement in behavior ... percent and 6 percent of preschool and school-aged ... upper airway obstruction. This condition is often associated ...
... researchers have identified a gene that causes benign moles on ... treat more effectively patients with early stages of melanoma. A ... Hopkins University, found a gene known as Id1 that causes ... suppressor gene that ordinarily keeps precancerous moles from progressing to ...
Cached Medicine News:Health News:Nobel Prize for Medicine 2Health News:Genetic failure in cloned animals 2Health News:Glucose may support in Cardiac Arrest 2Health News:Brain defect may play role in stammering 2Health News:Tonsillectomy improves quality of life 2Health News:Moles become cancerous due to genes 2